Skip to main content
Avicanna Inc. logo

Avicanna Inc. — Investor Relations & Filings

Ticker · AVCN ISIN · CA05368K1003 LEI · 254900AUQ4URGWO3FN90 TSX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2020-05-26 Management Reports
Country CA Canada
Listing TSX AVCN

About Avicanna Inc.

https://www.avicanna.com/

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based, cannabinoid-based products for the global medical and pharmaceutical markets. The company operates through four commercial pillars: Medical Cannabis Products (RHO Phyto™), a Medical Cannabis Care Platform (MyMedi.ca), a Pharmaceutical Pipeline, and Active Pharmaceutical Ingredients (Aureus Santa Marta™). Avicanna leverages an industry-leading scientific platform, including R&D collaborations with academic institutions and a robust IP portfolio, resulting in over 50 proprietary commercialized SKUs.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management's Discussion and Analysis of the Company' (MD&A) and contains detailed explanations of the company's financial results, business operations, strategic initiatives, and outlook for the quarter ended March 31, 2020. It includes forward-looking statements, quarterly highlights, business descriptions, research and development activities, and financial performance commentary. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial and operational analysis aligns with the characteristics of a Management Discussion and Analysis report, which is typically filed alongside or as part of interim or quarterly reports. Therefore, the document should be classified as a Management Reports (MDA) filing type.
2020-05-26 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109F2 Certification of Interim Filings by the CEO of Avicanna Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended March 31, 2020. The document is primarily an officer certification attesting to the accuracy and completeness of the interim filings, referencing National Instrument 52-109. It does not contain the actual interim financial statements or substantive financial data itself, but rather certifies those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is 3371 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2020-05-26 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CFO of Avicanna Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended March 31, 2020. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, including controls over financial reporting. It does not contain the actual interim financial statements or substantive financial data itself, but rather attests to their validity. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is 3371 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2020-05-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Avicanna Inc. Condensed Consolidated Interim Financial Statements (Unaudited) For the Three Months Ended March 31, 2020 and 2019' and contains detailed financial statements including statements of financial position, operations, changes in equity, and cash flows for a three-month period. It explicitly states it is an interim financial report prepared under IAS 34 Interim Financial Reporting. The document is approximately 15,000 characters long and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-05-26 English
News release - English.pdf
Regulatory Filings
2020-05-15 English
News release - English.pdf
Regulatory Filings
2020-05-14 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.